Introduction: Monitoring measurable residual disease (MRD) is crucial in acute myeloid leukaemia (AML), but molecular methods are only viable for about one-third of patients. This study aimed to validate a single tube multiparametric flow cytometry MRD (MFC-MRD) assay for service implementation.
Lam et al. (Sun,) studied this question.